- Home
- ALNY vs CTVA Comparison
ALNY vs CTVA Comparison
Compare ALNY & CTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALNY | CTVA |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Farming/Seeds/Milling |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.9B | 44.7B |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | ALNY | CTVA |
|---|---|---|
| Price | $394.40 | $68.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 28 | 17 |
| Target Price | ★ $479.45 | $77.81 |
| AVG Volume (30 Days) | 1.6M | ★ 3.4M |
| Earning Date | 02-12-2026 | 02-04-2026 |
| Dividend Yield | N/A | ★ 1.06% |
| EPS Growth | N/A | ★ 139.00 |
| EPS | 0.33 | ★ 2.35 |
| Revenue | $3,210,070,000.00 | ★ $17,469,000,000.00 |
| Revenue This Year | $70.04 | $6.91 |
| Revenue Next Year | $43.08 | $3.51 |
| P/E Ratio | $1,213.17 | ★ $28.86 |
| Revenue Growth | ★ 53.24 | 5.00 |
| 52 Week Low | $205.87 | $53.40 |
| 52 Week High | $495.55 | $77.41 |
Technical Indicators
Market Signals| Indicator | ALNY | CTVA |
|---|---|---|
| Relative Strength Index (RSI) | 36.34 | 61.42 |
| Support Level | $393.64 | $66.33 |
| Resistance Level | $407.22 | $67.98 |
| Average True Range (ATR) | 9.87 | 0.92 |
| MACD | 0.91 | 0.07 |
| Stochastic Oscillator | 36.05 | 86.89 |
Price Performance
Historical ComparisonAbout ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
About CTVA Corteva Inc.
Corteva is an agricultural inputs pure play that was formed in 2019 when it was spun off from DowDuPont. The company is a leader in the development of new seed and crop protection products. Seeds generate the majority of profits with the remainder coming from crop protection products. Corteva plans to spin off its seeds business in 2026 and will become a pure-play crop protection company following the divestiture. Corteva operates globally, but around half of revenue comes from North America.